Single- Versus Multi-Fraction Stereotactic Body Radiotherapy for Primary Lung Cancer and Pulmonary Oligometastases: A Systematic Review and Meta-Analyses.

Authors

Ishaan Pillay, Harriet Gee, Eric Hau, Anselm Ong, Val Gebski

Published in

JTO clinical and research reports. Volume 7. Issue 9. Pages 101005. Epub Apr 21, 2026.

Abstract

Stereotactic body radiation therapy (SBRT), the standard of care for medically inoperable early-stage NSCLC, is increasingly used for pulmonary oligometastases. Optimal fractionation-single fraction (SF) versus multiple fractions (MF)-remains unclear, as existing randomized studies lack power to confirm SF noninferiority in local control. This review assessed 2-year local failure (LF) rates for SF versus MF SBRT. PubMed, Ovid Medline, and the Cochrane Library were searched. Titles and abstracts were reviewed followed by full-text review. Studies reporting LF outcomes for SF or MF SBRT in early-stage NSCLC or pulmonary metastases were included. Preferred Reporting Items for Systematic Reviews and Meta-Analyses and Cochrane Handbook for Systematic Reviews guidelines were followed. Pooled estimates were calculated using fixed- and random-effects models. Primary lung cancers treated with biologically effective doses (BED₁₀) ≥100 Gy demonstrated similar 2-year LF rates with SF and MF SBRT. However, unclear T1/T2 classification may contribute to selection bias, as MF is often used for larger tumors. SF SBRT was associated with an 8.25% higher LF rate in cohorts treated with BED₁₀ <100 Gy. Pulmonary metastases treated with SF demonstrated a 4% higher LF rate compared with MF, although substantial heterogeneity limited confidence in this finding. Limited data demonstrated the highest 2-year LF rates (25.6%) in colorectal oligometastases. Overall, SF SBRT appears to provide similar 2-year LF outcomes to MF in primary lung cancer when adequate BED is delivered, although cautious guideline application is warranted given the predominance of retrospective studies and limited data for larger or radioresistant tumors. MF may offer modest benefit for pulmonary metastases.

PMID:
42657018
Bibliographic data and abstract were imported from PubMed on 27 Aug 2026.

Read full publication at:
Please sign in to see all details.

Stats

1-terrible, 9-excellent. How would you rate this publication? Sign in in to submit your rating.

Post a comment

You need to be signed in to post comments. You can sign in here.

Comments

There are no comments yet.